Patents by Inventor Colin Zhang

Colin Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11053246
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 6, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • Patent number: 10968221
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula IIa, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: April 6, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Publication number: 20200377504
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: April 7, 2020
    Publication date: December 3, 2020
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Yaping Sun, Liang Lu, Ding-Quan Qian, Meizhong Xu, Jincong Zhuo, Wenqing Yao
  • Patent number: 10813930
    Abstract: The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: October 27, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Wenqing Yao, Colin Zhang, Meizhong Xu, Jincong Zhuo, Chunhong He
  • Publication number: 20200317680
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Patent number: 10738052
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 11, 2020
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Patent number: 10640503
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Patent number: 10556908
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Publication number: 20200024277
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 3, 2019
    Publication date: January 23, 2020
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Publication number: 20190240220
    Abstract: The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: January 2, 2019
    Publication date: August 8, 2019
    Inventors: Wenqing Yao, Colin Zhang, Meizhong Xu, Jincong Zhuo, Chunhong He
  • Publication number: 20190152976
    Abstract: The present invention is directed to [1,2,4]triazolo[4,3-a]pyridine and [1,2,4]triazolo[4,3-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 23, 2019
    Inventors: Liangxing Wu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Publication number: 20190127376
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: October 5, 2018
    Publication date: May 2, 2019
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Yaping Sun, Liang Lu, Ding-Quan Qian, Meizhong Xu, Jincong Zhuo, Wenqing Yao
  • Publication number: 20190119272
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: September 27, 2018
    Publication date: April 25, 2019
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Publication number: 20190106426
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: September 13, 2018
    Publication date: April 11, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Patent number: 10213427
    Abstract: The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 26, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Wenqing Yao, Colin Zhang, Meizhong Xu, Jincong Zhuo, Chunhong He
  • Publication number: 20190040058
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: July 18, 2018
    Publication date: February 7, 2019
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Patent number: 10138249
    Abstract: The present invention is directed to [1,2,4]triazolo[4,3-a]pyridine and [1,2,4]triazolo[4,3-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: November 27, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Patent number: 10131667
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: November 20, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • Patent number: 10125133
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: November 13, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Patent number: 10112950
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 30, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo